In conclusion, there is still not enough evidence to indicate an association between TLR9 gene rs187084, rs352139, and rs352140 polymorphisms and the development of SLE in the Asian population.
Our study suggests that a single nucleotide polymorphism (rs352140</span>) in the exon 2 region of TLR9 gene may be a susceptibility factor for SLE in Chinese population.
Therefore, we studied the distribution of the TLR9 C > T (rs352140) polymorphism in patients with SLE (n = 254) and controls (n = 521) in a Polish population.
We analyzed the frequency of TLR7 rs179008, TLR8 rs3764880, TLR9 rs5743836 and rs352140 in 370 patients with SLE and 415 healthy controls from southern Brazil.
Furthermore, no association was found between the rs5744168 (TLR5) polymorphism and SLE susceptibility in Europeans or between the rs187084 (TLR8) or rs352140 (TLR9) polymorphisms and SLE susceptibility in Asians.
Logistic regression analyses showed that the rs187</span>084 heterozygote TC was associated with a significantly increased risk of cervical cancer (adjusted OR=1.28, 95% CI=1.01-1.62), compared with the TT genotype.
Furthermore, no association was found between the rs5744168 (TLR5) polymorphism and SLE susceptibility in Europeans or between the rs187084 (TLR8) or rs352140 (TLR9) polymorphisms and SLE susceptibility in Asians.
Our results revealed that the associations between rs187084</span> and ce</span>rvical cancer risk in the dominant model (<i>p</i> = 0.002) and heterozygous model (<i>p</i> = 0.002) were significant, with 1.30- and 1.32-fold increases in susceptibility, respectively, compared to that in the wild-type model.
The results showed that the rs187084 polymorphism was significantly associated with an increased risk of cancer (CC vs TC+TT: OR=1.14, 95% CI=1.02-1.28), specifically cervical cancer (C vs T: OR=1.19, 95% CI=1.05-1.34; TC vs TT: OR=1.32, 95% CI=1.10-1.58; CC vs TT: OR=1.31, 95% CI= 1.03-1.68; CC+TC vs TT: OR=1.32, 95% CI=1.11-1.56), and that this association was significantly positive in Caucasians (CC vs. TC+TT: OR=1.18, 95% CI=1.01-1.38).
CC and CT genotypes of TLR4 rs11536889 and rs1927911 respectively, and TC, CC genotypes of TLR9 rs187084, as well as minor alleles of TLR4 rs4986790 and TLR9 rs187084, were associated with the increased risk of cervical cancer.
When available studies were pooled into the meta-analysis, there was no evidence showing a significant association between rs187084 and SLE risk in an Asian population (for C vs. T: OR = 0.81, P = 0.117; for CC vs. TT: OR = 0.71, P = 0.158; for CT vs. TT: OR = 0.86, P = 0.085; for CC + CT vs. TT: OR = 0.78, P = 0.093; for CC vs. CT + TT: OR = 0.81, P = 0.285).
The results showed that the rs187084 polymorphism was significantly associated with an increased risk of cancer (CC vs TC+TT: OR=1.14, 95% CI=1.02-1.28), specifically cervical cancer (C vs T: OR=1.19, 95% CI=1.05-1.34; TC vs TT: OR=1.32, 95% CI=1.10-1.58; CC vs TT: OR=1.31, 95% CI= 1.03-1.68; CC+TC vs TT: OR=1.32, 95% CI=1.11-1.56), and that this association was significantly positive in Caucasians (CC vs. TC+TT: OR=1.18, 95% CI=1.01-1.38).
The results showed that the rs187084 polymorphism was significantly associated with an increased risk of cancer (CC vs TC+TT: OR=1.14, 95% CI=1.02-1.28), specifically cervical cancer (C vs T: OR=1.19, 95% CI=1.05-1.34; TC vs TT: OR=1.32, 95% CI=1.10-1.58; CC vs TT: OR=1.31, 95% CI= 1.03-1.68; CC+TC vs TT: OR=1.32, 95% CI=1.11-1.56), and that this association was significantly positive in Caucasians (CC vs. TC+TT: OR=1.18, 95% CI=1.01-1.38).
Logistic regression analyses showed that the rs187</span>084 heterozygote TC was associated with a significantly increased risk of cervical cancer (adjusted OR=1.28, 95% CI=1.01-1.62), compared with the TT genotype.
CC and CT genotypes of TLR4 rs11536889 and rs1927911 respectively, and TC, CC genotypes of TLR9 rs187084, as well as minor alleles of TLR4 rs4986790 and TLR9 rs187084, were associated with the increased risk of cervical cancer.
Our results revealed that the associations between rs187084</span> and ce</span>rvical cancer risk in the dominant model (<i>p</i> = 0.002) and heterozygous model (<i>p</i> = 0.002) were significant, with 1.30- and 1.32-fold increases in susceptibility, respectively, compared to that in the wild-type model.
Logistic regression analyses showed that the rs187</span>084 heterozygote TC was associated with a significantly increased risk of cervical cancer (adjusted OR=1.28, 95% CI=1.01-1.62), compared with the TT genotype.